Tag Archives: TRVN

Top 5 High Tech Stocks To Buy Right Now

SAN FRANCISCO The T in Twitter might as well stand for turmoil.

Just weeks after its chief operating officer resigned, the company this week lost two more senior executives, including its chief technology officer.

The unexpected departures pummeledthestock (TWTR), which ended the week down 11%. Some analysts believe shares, now trading in the $16 range from near $19 a week ago,could retreat to their low, below $14, as investors loseconfidence in founder Jack Dorsey. That would be a very steep decline from itsinitial trading price of $44.94in 2013 and its all-time high of $74.73.

“One C-Level departure is a red flag; two in a quarter is very disconcerting,” Mizuho Securities analyst Neil Doshi said in research note. “We view C-Level changes as red flags for any business, and two unexpected C-level changes in a short period of time could, in our opinion, create significant investment risks.”

Top 5 High Tech Stocks To Buy Right Now: Norsat International Inc.(NSAT)

Advisors’ Opinion:

  • [By Lisa Levin]

    Shares of Norsat International Inc (USA) (NYSE: NSAT) got a boost, shooting up 22 percent to $9.85 after the company reported the receipt of new indication of interest by Privet Fund Management LLP at $10.25 per share.

Top 5 High Tech Stocks To Buy Right Now: Trevena, Inc.(TRVN)

Advisors’ Opinion:

  • [By Lisa Levin]

    Trevena Inc (NASDAQ: TRVN) shares dropped 36 percent to $4.55 despite a positive development in Phase 3 trials. Trevena announced positive top-line results from ongoing Phase 3 trials called "APOLLO-1" and "APOLLO-2." The studies evaluated the safety of Trevena's oliceridine therapy in patients for 48 hours following bunionectomy and 24 hours following abdominoplasty.

  • [By Maxx Chatsko]

    Shares of clinical-stage biopharma Trevena (NASDAQ:TRVN) fell nearly 12% today after it reported full-year 2016 earnings. The pre-revenue company didn’t announce any surprises one way or the other. However, investors appear to be considering the near-term consequences of swelling expenses that won’t be offset by product sales anytime soon.

  • [By Paul Ausick]

    Trevena Inc. (NASDAQ: TRVN) dropped about 6.3% Thursday, to post a new 52-week low of $3.70 after closing at $3.95 on Wednesday. The stock’s 52-week high is $9.73. Volume was nearly 5 times the daily average of around 700,000 shares. The company’s pain-killing drug got mixed results in a trial result reported Tuesday.

Top 5 High Tech Stocks To Buy Right Now: OncoSec Medical Incorporated(ONCS)

Advisors’ Opinion:

  • [By Lisa Levin]

     

    Losers
    DBV Technologies SA – ADR (NASDAQ: DBVT) shares tumbled 50.6 percent to $23.73 after the company disclosed that its peanut allergy trial failed to meet primary endpoint.
    Connecture Inc (NASDAQ: CNXR) shares declined 40.8 percent to $0.290. Connecture reported that it will voluntarily delist from the NASDAQ for OTCQX Market.
    Walter Investment Management Corp (NYSE: WAC) slipped 19.2 percent to $0.410. On Friday, Walter Investment Management disclosed that it has reached an agreement with term lenders and senior noteholders on financial restructuring.
    Eldorado Gold Corp (USA) (NYSE: EGO) shares dropped 15.9 percent to $1.83. Eldorado Gold lowered its production guidance for its Kisladag operation.
    Seanergy Maritime Holdings Corp. (NASDAQ: SHIP) shares fell 15.4 percent to $1.04.
    Future Fintech Group Inc (NASDAQ: FTFT) dropped 13.6 percent to $1.53. Future FinTech reported filing of proxy statement, including proposal for corporate restructuring.
    Concordia International Corp (NASDAQ: CXRX) shares fell 12.3 percent to $0.500 after dipping 38.71 percent on Friday.
    Aemetis Inc (NASDAQ: AMTX) shares declined 11.3 percent to $0.550
    OncoSec Medical Inc (NASDAQ: ONCS) dipped 10.5 percent to $1.12. OncoSec reported a $7.1 million registered direct at-the-market offering at a price of $1.34375 per share.
    Evoke Pharma Inc (NASDAQ: EVOK) shares fell 10.35 percent to $3.08 after the company disclosed 'positive' topline results from comparative exposure pharmacokinetic study for Gimoti.
    Eiger Biopharmaceuticals Inc (NASDAQ: EIGR) shares dropped 9.4 percent to $11.60 as the company disclosed Phase 2 interim 24-week data with pegylated interferon lambda in Hepatitis Delta Virus infection at the American Association for the Study of Liver Diseases Meeting.
    Viking Therapeutics Inc (NASDAQ: VKTX) shares slipped 6.6 percent to $2.80. Viking Therapeutics presented results from proof-of-concept study of VK0214 in in vivo

Top 5 High Tech Stocks To Buy Right Now: Valhi Inc.(VHI)

Advisors’ Opinion:

  • [By Lisa Levin]

    In trading on Thursday, basic materials shares slipped by 0.61 percent. Meanwhile, top losers in the sector included Valhi, Inc. (NYSE: VHI), down 13 percent, and LSB Industries, Inc. (NYSE: LXU), down 7 percent.

Top 5 High Tech Stocks To Buy Right Now: PACCAR Inc.(PCAR)

Advisors’ Opinion:

  • [By JPMorgan]

    We are Neutral on PCAR as the company faces the risk of both lower volume and margin pressure from declining demand in its core NA HD truck business in 2016. However, we believe PCAR should command a premium valuation due to its track record of solid execution. In addition, PCAR pays out a normal and a special dividend which, in total, should equal ~50% of net income and currently offers a yield of 4.1% (JPMe total payout of ~$2.12/share) making it potentially attractive to income-oriented investors. 

  • [By WWW.THESTREET.COM]

    In the Lightning Round, Cramer was bullish on Salesforce.com (CRM) , Paccar (PCAR) , Cummins (CMI) , ConocoPhillips (COP) , Adobe Systems (ADBE) , Annaly Capital (NLY) and Hewlett Packard Enterprise (HPE) .

  • [By Jim Cramer]

    The net income growth from the same quarter one year ago has significantly exceeded that of the S&P 500 and the Machinery industry. The net income increased by 16.1% when compared to the same quarter one year prior, going from $371.40 million to $431.20 million.

     

Hot Biotech Stocks For 2018

What happened

Shares of Novavax, Inc. (NASDAQ:NVAX), a clinical-stage biotech developing vaccines, have risen about 10.7% as of 3:05 p.m. EDT on Thursday. A positive response to the company’s earnings pushed the stock up a couple days ago, but Thursday’s bump comes in response to recent insider share purchases.

So what

Earlier Thursday morning Novavax filed a couple forms the U.S. Securities and Exchange Commission requires when insiders buy or sell shares. There are a million reasons for insiders to sell shares of the company they work for, but just one reason to buy. That’s why investors were thrilled to see the company’s CEO, StanleyErck, and CFO, Barclay “Buck” Phillips, broadcast their positive outlook with a combined purchase of 75,000 shares.

Image source: Getty Images.

You should never blindly follow the trading activity of others, even if they’re running the company. As with the recent post-earnings bump, there just isn’t much here to get excited about.

Hot Biotech Stocks For 2018: SCIENCE APPLICATIONS INTERNATIONAL CORPORATION(SAIC)

Advisors’ Opinion:

  • [By Monica Gerson]

    Science Applications International Corp (NYSE: SAIC) is estimated to report its quarterly earnings at $0.74 per share on revenue of $1.15 billion.

  • [By Lisa Levin]

    Gainers

    Pyxis Tankers Inc. (NYSE: PXS) rose 47.48 percent to $$5.56, after the company announced it has entered into a definitive securities purchase agreement with a group of investors, which will result in gross proceeds of $4.8 million.
    Sigma Designs Inc (NASDAQ: SIGM) rose 22.77 percent to $6.88. Silicon Laboratories (NASDAQ: SLAB) announced plans to buy Sigma Designs for $7.05 per share in cash.
    Steadymed Ltd (NASDAQ: STDY) rose 19.35 percent to $3.70, after the company reported that no clinical trials were required for Trevyent and that the FDA had agreed to the pathway for the drug candidate's NDA resubmission.
    Iteris, Inc. (NASDAQ: ITI) rose 15.73 percent to $7.06. Earlier in the week, Zacks Investment Research had upgraded the company from "Sell" to "Hold".
    Science Applications International Corp (NYSE: SAIC) rose 13.71 percent to $85.77 as the company reported better-than-expected earnings for its third quarter.
    Technical Communications Corporation (NASDAQ: TCCO) rose 12.41 percent to $6.07, after having risen sharply in pre-marketing trading.
    Radius Health, Inc. (NASDAQ: RDUS) rose 12.41 percent to $30.81 after the company provided an update on data from the Phase 1 005 clinical study of elacestrant in patients with estrogen receptor positive breast cancer during the 2017 San Antonio Breast Cancer Symposium.
    ForeScout Technologies, Inc. (NASDAQ: FSCT) rose 12.32 percent to $25.80 after the company reported its third quarter financial results.
    Prana Biotechnology Limited (NASDAQ: PRAN) rose 11.36 percent to $3.43, as the company announced a research collaboration with Takeda Pharmaceuticals to study the ability of movement disorders compound, PBT434 to slow or prevent neurodegeneration of the gastrointestinal system.
    Catalyst Biosciences, Inc. (NASDAQ: CBIO) rose 10.49 percent to $7.90 as the company announced the appointment of Arwa Shurrab and Jamie Ellen Siegel in its clinical hemophilia

  • [By Monica Gerson]

    Wall Street expects Science Applications International Corp (NYSE: SAIC) to report its quarterly earnings at $0.74 per share on revenue of $1.15 billion. SAIC shares gained 0.96 percent to $57.87 in after-hours trading.

Hot Biotech Stocks For 2018: 21Vianet Group, Inc.(VNET)

Advisors’ Opinion:

  • [By Leo Sun]

    In a previous article, I reviewed why GoPro, Twilio, and Wuba.com were all cut in half in 2016. Today I’ll add two Chinese tech stocks to that list — Renren (NYSE:RENN) and 21Vianet (NASDAQ:VNET) — which both lost more than half their value over the past 12 months.

  • [By Monica Gerson]

    21Vianet Group Inc (NASDAQ: VNET) shares rose 5.88 percent to $15.30 in the pre-market trading session as the company reported a $388 million investment by TUS Holdings.

Hot Biotech Stocks For 2018: Trevena, Inc.(TRVN)

Advisors’ Opinion:

  • [By Lisa Levin]

    Trevena Inc (NASDAQ: TRVN) shares dropped 36 percent to $4.55 despite a positive development in Phase 3 trials. Trevena announced positive top-line results from ongoing Phase 3 trials called "APOLLO-1" and "APOLLO-2." The studies evaluated the safety of Trevena's oliceridine therapy in patients for 48 hours following bunionectomy and 24 hours following abdominoplasty.

  • [By Lisa Levin] Gainers
    Trevena Inc (NASDAQ: TRVN) rose 10.8 percent to $3.60 in pre-market trading after dropping 4.97 percent on Wednesday.
    Yum China Holdings Inc (NYSE: YUMC) rose 10.2 percent to $31.05 in pre-market trading after the company reported upbeat earnings for its first quarter.
    Seres Therapeutics Inc (NASDAQ: MCRB) rose 9.1 percent to $11.39 in pre-market trading after dropping 5.26 percent on Wednesday.
    Plug Power Inc (NASDAQ: PLUG) rose 8.9 percent to $2.45 in pre-market trading after surging 73.08 percent on Wednesday.
    Coach Inc (NYSE: COH) rose 6.7 percent to $41.98 in pre-market trading. Coach named Ian Bickley as President, Global Business Development and Strategic Alliances.
    Sapiens International Corporation N.V. (NASDAQ: SPNS) shares rose 6.1 percent to $13.91 in pre-market trading after gaining 0.54 percent on Wednesday.
    Jazz Pharmaceuticals plc (NASDAQ: JAZZ) rose 6.1 percent to $149.15 in pre-market trading. Jazz Pharma reached a settlement with Hikma Pharma related to Xyrem patent case. Mizuho downgraded Jazz from Buy to Neutral.
    Interactive Brokers Group, Inc. (NASDAQ: IBKR) shares rose 6 percent to $36.72 in pre-market trading after declining 0.03 percent on Wednesday.
    Rewalk Robotics Ltd (NASDAQ: RWLK) rose 5.3 percent to $2.00 in pre-market trading after the company disclosed that the U.S. Department of Veterans Affairs purchased 28 added Exoskeleton Systems.
    Merrimack Pharmaceuticals Inc (NASDAQ: MACK) rose 5.1 percent to $3.29 in pre-market trading. Merrimack declared a $1.06 special dividend.
    BioTime, Inc. (NYSE: BTX) shares rose 4.8 percent to $3.50 in pre-market trading. BioTime, reported the formation of new subsidiary AgeX Therapeutics, Inc.
    Akari Therapeutics PLC (ADR) (NASDAQ: AKTX) shares rose 4.8 percent to $12.26 in pre-market trading after gaining 0.69 percent on Wednesday.
    Bed Bath & Beyond Inc. (NASDAQ: BBBY) rose 3.6 percent to $39.15 in pre-market trading after the company posted better-than
  • [By Paul Ausick]

    Trevena Inc. (NASDAQ: TRVN) dropped about 6.3% Thursday, to post a new 52-week low of $3.70 after closing at $3.95 on Wednesday. The stock’s 52-week high is $9.73. Volume was nearly 5 times the daily average of around 700,000 shares. The company’s pain-killing drug got mixed results in a trial result reported Tuesday.

  • [By Chris Lange]

    Trevena Inc. (NASDAQ: TRVN) reported positive results from two late-stage clinical trials that work to treat post-surgical pain. The company intends to submit these results to the FDA for a marketing approval agreement in the fourth quarter. Previously, oliceridine was approved for a breakthrough designation by the agency.

  • [By Maxx Chatsko]

    Shares of clinical-stage biopharma Trevena (NASDAQ:TRVN) fell nearly 12% today after it reported full-year 2016 earnings. The pre-revenue company didn’t announce any surprises one way or the other. However, investors appear to be considering the near-term consequences of swelling expenses that won’t be offset by product sales anytime soon.

Top Safest Stocks To Watch For 2018

It’s been three trading days since the U.S. Federal reserve hiked interest rates–and the stock market has been moribund ever since.

Getty Images

The S&P 500 declined 0.2% to 2,373.47 today, while the Dow Jones Industrial Average dipped 8.76 points to 20,905.86. The Nasdaq Composite finished little changed at 5,901.53. The Dow Jones Industrial Average has dipped44.24 points, or 0.2%, over the last three trading days.

Ameriprise Financial’s David Joy is already looking ahead to the next rate hike:

The Fed has three remaining meetings throughout the year that are accompanied by updated economic projections and press conferences, in June, September, and December. While the Fed insists that all Federal Open Markets Committee (FOMC) meetings are live, meaning opportunities for changes in monetary policy, it is widely assumed that the press conference meetings are the more likely candidates. Although some believe the Fed is in danger of falling behind the curve, unless the economic data accelerates sharply, especially on the inflation front, it seems unlikely that the Fed would want to raise again as early as June. Three rate hikes in six months after just one in the previous twelve might be too aggressive a shift in policy. Nevertheless, futures suggest better than even odds that another rate hike will come in June. More likely, the Fed waits to observe conditions a little longer, targeting September for its next move.

Top Safest Stocks To Watch For 2018: Stryker Corporation(SYK)

Advisors’ Opinion:

  • [By Jayson Derrick]

    Stryker Corporation (NYSE: SYK)’s stock fell nearly 5 percent on Aug. 23 as investors were troubled with the company’s recall announcement, Argus’ David Toung noted in a separate research report. But investors may want to consider taking advantage of the selloff as it represents a “favorable investment opportunity.”

  • [By Lisa Levin]

    Shares of Entellus Medical Inc (NASDAQ: ENTL) got a boost, shooting up 49 percent to $23.82. Stryker Corporation (NYSE: SYK) announced plans to acquire Entellus Medical for $24 per share in cash.

Top Safest Stocks To Watch For 2018: ZIOPHARM Oncology Inc(ZIOP)

Advisors’ Opinion:

  • [By Lisa Levin]

    In trading on Friday, healthcare shares fell by 0.88 percent. Meanwhile, top losers in the sector included Simulations Plus, Inc. (NASDAQ: SLP), down 7 percent, and ZIOPHARM Oncology Inc. (NASDAQ: ZIOP), down 7 percent.

Top Safest Stocks To Watch For 2018: Capricor Therapeutics, Inc.(CAPR)

Advisors’ Opinion:

  • [By Lisa Levin] Gainers
    Marathon Patent Group Inc (NASDAQ: MARA) shares surged 30.2 percent to $5.01 after dropping 40.86 percent on Tuesday. Marathon Patent Group filed for sale of 1.85 million shares of common stock by selling stockholders.
    Capricor Therapeutics Inc (NASDAQ: CAPR) shares jumped 17.2 percent to $2.25 after the company reported the FDA clearance of Investigational New Drug application for CAP-1002.
    Rite Aid Corporation (NYSE: RAD) gained 13.2 percent to $2.15 following 16.5 percent rally on Tuesday.
    Photronics, Inc. (NASDAQ: PLAB) shares climbed 11.8 percent to $10.45 after the company reported stronger-than-expected earnings for its fourth quarter.
    China Distance Education Hldgs Ltd (ADR) (NYSE: DL) shares surged 11.3 percent to $8.67. China Distance Education reported Q4 profit of $5.9 million on revenue of $41.7 million.
    Cytokinetics, Inc. (NASDAQ: CYTK) shares gained 11 percent to $8.05 after falling 7.05 percent on Tuesday.
    Ooma Inc (NYSE: OOMA) shares surged 8.5 percent to $10.85 as the company posted strong Q3 results.
    Nuance Communications Inc. (NASDAQ: NUAN) climbed 8 percent to $17.12 after the company reported stronger-than-expected results for its fourth quarter on Tuesday.
    American Superconductor Corporation (NASDAQ: AMSC) surged 7.8 percent to $3.59 after the company reported $8 million in D-VAR system orders.
    Thermon Group Holdings Inc (NYSE: THR) rose 6.3 percent to $24.17. William Blair upgraded Thermon Group from Market Perform to Outperform.
    Domino's Pizza, Inc. (NYSE: DPZ) surged 6.1 percent to $182.88. Nomura upgraded Domino's from Neutral to Buy.
    Xencor Inc (NASDAQ: XNCR) rose 5.9 percent to $21.17. Cantor Fitzgerald initiated coverage on Xencor with an Overweight rating.
    Idera Pharmaceuticals Inc (NASDAQ: IDRA) gained 5.1 percent to $2.28 after the company disclosed that it has been granted FDA Fast Track designation for IMO-2125.
    Regal Entertainment Group (NYSE: RGC) gained 5.1 percent to

Top Safest Stocks To Watch For 2018: Trevena, Inc.(TRVN)

Advisors’ Opinion:

  • [By Maxx Chatsko]

    Shares of clinical-stage biopharma Trevena (NASDAQ:TRVN) fell nearly 12% today after it reported full-year 2016 earnings. The pre-revenue company didn’t announce any surprises one way or the other. However, investors appear to be considering the near-term consequences of swelling expenses that won’t be offset by product sales anytime soon.

  • [By Lisa Levin]

    Trevena Inc (NASDAQ: TRVN) shares dropped 36 percent to $4.55 despite a positive development in Phase 3 trials. Trevena announced positive top-line results from ongoing Phase 3 trials called "APOLLO-1" and "APOLLO-2." The studies evaluated the safety of Trevena's oliceridine therapy in patients for 48 hours following bunionectomy and 24 hours following abdominoplasty.

  • [By Chris Lange]

    Trevena Inc. (NASDAQ: TRVN) reported positive results from two late-stage clinical trials that work to treat post-surgical pain. The company intends to submit these results to the FDA for a marketing approval agreement in the fourth quarter. Previously, oliceridine was approved for a breakthrough designation by the agency.

  • [By Paul Ausick]

    Trevena Inc. (NASDAQ: TRVN) dropped about 6.3% Thursday, to post a new 52-week low of $3.70 after closing at $3.95 on Wednesday. The stock’s 52-week high is $9.73. Volume was nearly 5 times the daily average of around 700,000 shares. The company’s pain-killing drug got mixed results in a trial result reported Tuesday.

  • [By Lisa Levin] Gainers
    Trevena Inc (NASDAQ: TRVN) rose 10.8 percent to $3.60 in pre-market trading after dropping 4.97 percent on Wednesday.
    Yum China Holdings Inc (NYSE: YUMC) rose 10.2 percent to $31.05 in pre-market trading after the company reported upbeat earnings for its first quarter.
    Seres Therapeutics Inc (NASDAQ: MCRB) rose 9.1 percent to $11.39 in pre-market trading after dropping 5.26 percent on Wednesday.
    Plug Power Inc (NASDAQ: PLUG) rose 8.9 percent to $2.45 in pre-market trading after surging 73.08 percent on Wednesday.
    Coach Inc (NYSE: COH) rose 6.7 percent to $41.98 in pre-market trading. Coach named Ian Bickley as President, Global Business Development and Strategic Alliances.
    Sapiens International Corporation N.V. (NASDAQ: SPNS) shares rose 6.1 percent to $13.91 in pre-market trading after gaining 0.54 percent on Wednesday.
    Jazz Pharmaceuticals plc (NASDAQ: JAZZ) rose 6.1 percent to $149.15 in pre-market trading. Jazz Pharma reached a settlement with Hikma Pharma related to Xyrem patent case. Mizuho downgraded Jazz from Buy to Neutral.
    Interactive Brokers Group, Inc. (NASDAQ: IBKR) shares rose 6 percent to $36.72 in pre-market trading after declining 0.03 percent on Wednesday.
    Rewalk Robotics Ltd (NASDAQ: RWLK) rose 5.3 percent to $2.00 in pre-market trading after the company disclosed that the U.S. Department of Veterans Affairs purchased 28 added Exoskeleton Systems.
    Merrimack Pharmaceuticals Inc (NASDAQ: MACK) rose 5.1 percent to $3.29 in pre-market trading. Merrimack declared a $1.06 special dividend.
    BioTime, Inc. (NYSE: BTX) shares rose 4.8 percent to $3.50 in pre-market trading. BioTime, reported the formation of new subsidiary AgeX Therapeutics, Inc.
    Akari Therapeutics PLC (ADR) (NASDAQ: AKTX) shares rose 4.8 percent to $12.26 in pre-market trading after gaining 0.69 percent on Wednesday.
    Bed Bath & Beyond Inc. (NASDAQ: BBBY) rose 3.6 percent to $39.15 in pre-market trading after the company posted better-than

stock market indicators

Most of us need to accumulate a significant war chest for retirement that can produce much-needed income to supplement Social Security checks. It’s smart to devise a retirement plan early — and to consider making a Roth IRA a part of it.

A Roth IRA offers some meaningful tax advantages. For example, your contributions will grow over time and your withdrawals in retirement can be free of federal taxes! Withdrawals from a traditional IRA are taxed as ordinary income in federal and state taxes. Let’s take a closer look at how IRAs (especially Roth IRAs) can strengthen your future financial security and eventually provide valuable retirement income.

Image source: Getty Images.

Traditional and Roth IRAs can enhance your retirement

Let’s first review just what IRAs are and how they work. There are two main kinds of IRAs — the traditional IRA and the Roth IRA. With a traditional IRA, you contribute pre-tax money, reducing your taxable income for the year, and thereby reducing your taxes, too. (Taxable income of $75,000 and a $5,000 contribution? You’ll only report $70,000 in taxable income for the year.) The money grows in your account and is taxed at your ordinary income tax rate when you withdraw it in retirement. Many of us will be in lower tax brackets in retirement, so not only is our taxation postponed, but it’s often reduced. That’s the tax break you get with a traditional IRA.

stock market indicators: Deckers Outdoor Corporation(DECK)

Advisors’ Opinion:

  • [By Ben Levisohn]

    Hanesbrands was just one of many retail companies that got shellacked this week. Under Armour (UAA) tumbled 29% after missing earnings forecasts and cutting its guidance, while Deckers Outdoor (DECK) plunged 21% after its earnings missed the Street consensus, and Ralph Lauren (RL) plummeted 13% after its CEO stepped down.

  • [By Taylor Cox]

    Analyst/Investor Days

    Finjan Holdings, Inc (NASDAQ: FNJN)
    Danaher Corporation (NYSE: DHR)
    Delta Air Lines, Inc (NYSE: DAL)
    Deckers Outdoor Corporation (NYSE: DECK) annual shareholder meeting, to vote on Marcato Capital board nominees

    Legal

  • [By Matt Hogan]

    SKX is also highly attractive in a relative basis when compared to several of its publicly traded peers: Foot Locker, Inc. (NYSE: FL), Deckers Outdoor Group (NYSE: DECK), Wolverine World Wide, Inc. (NYSE: WWW) and Columbia Sportswear Company (NASDAQ: COLM). The company's forward EBITDA multiple of 6.9x is equal or below all of the comparable companies: FL (6.9x), DECK (7.6x), WWW (10.1x) and COLM (10.8x).

stock market indicators: Trevena, Inc.(TRVN)

Advisors’ Opinion:

  • [By Lisa Levin] Gainers
    Trevena Inc (NASDAQ: TRVN) rose 10.8 percent to $3.60 in pre-market trading after dropping 4.97 percent on Wednesday.
    Yum China Holdings Inc (NYSE: YUMC) rose 10.2 percent to $31.05 in pre-market trading after the company reported upbeat earnings for its first quarter.
    Seres Therapeutics Inc (NASDAQ: MCRB) rose 9.1 percent to $11.39 in pre-market trading after dropping 5.26 percent on Wednesday.
    Plug Power Inc (NASDAQ: PLUG) rose 8.9 percent to $2.45 in pre-market trading after surging 73.08 percent on Wednesday.
    Coach Inc (NYSE: COH) rose 6.7 percent to $41.98 in pre-market trading. Coach named Ian Bickley as President, Global Business Development and Strategic Alliances.
    Sapiens International Corporation N.V. (NASDAQ: SPNS) shares rose 6.1 percent to $13.91 in pre-market trading after gaining 0.54 percent on Wednesday.
    Jazz Pharmaceuticals plc (NASDAQ: JAZZ) rose 6.1 percent to $149.15 in pre-market trading. Jazz Pharma reached a settlement with Hikma Pharma related to Xyrem patent case. Mizuho downgraded Jazz from Buy to Neutral.
    Interactive Brokers Group, Inc. (NASDAQ: IBKR) shares rose 6 percent to $36.72 in pre-market trading after declining 0.03 percent on Wednesday.
    Rewalk Robotics Ltd (NASDAQ: RWLK) rose 5.3 percent to $2.00 in pre-market trading after the company disclosed that the U.S. Department of Veterans Affairs purchased 28 added Exoskeleton Systems.
    Merrimack Pharmaceuticals Inc (NASDAQ: MACK) rose 5.1 percent to $3.29 in pre-market trading. Merrimack declared a $1.06 special dividend.
    BioTime, Inc. (NYSE: BTX) shares rose 4.8 percent to $3.50 in pre-market trading. BioTime, reported the formation of new subsidiary AgeX Therapeutics, Inc.
    Akari Therapeutics PLC (ADR) (NASDAQ: AKTX) shares rose 4.8 percent to $12.26 in pre-market trading after gaining 0.69 percent on Wednesday.
    Bed Bath & Beyond Inc. (NASDAQ: BBBY) rose 3.6 percent to $39.15 in pre-market trading after the company posted better-than
  • [By Paul Ausick]

    Trevena Inc. (NASDAQ: TRVN) dropped about 6.3% Thursday, to post a new 52-week low of $3.70 after closing at $3.95 on Wednesday. The stock’s 52-week high is $9.73. Volume was nearly 5 times the daily average of around 700,000 shares. The company’s pain-killing drug got mixed results in a trial result reported Tuesday.

  • [By Chris Lange]

    Trevena Inc. (NASDAQ: TRVN) reported positive results from two late-stage clinical trials that work to treat post-surgical pain. The company intends to submit these results to the FDA for a marketing approval agreement in the fourth quarter. Previously, oliceridine was approved for a breakthrough designation by the agency.

  • [By Lisa Levin]

    Trevena Inc (NASDAQ: TRVN) shares dropped 36 percent to $4.55 despite a positive development in Phase 3 trials. Trevena announced positive top-line results from ongoing Phase 3 trials called "APOLLO-1" and "APOLLO-2." The studies evaluated the safety of Trevena's oliceridine therapy in patients for 48 hours following bunionectomy and 24 hours following abdominoplasty.

  • [By Maxx Chatsko]

    Shares of clinical-stage biopharma Trevena (NASDAQ:TRVN) fell nearly 12% today after it reported full-year 2016 earnings. The pre-revenue company didn’t announce any surprises one way or the other. However, investors appear to be considering the near-term consequences of swelling expenses that won’t be offset by product sales anytime soon.

stock market indicators: Coca-Cola Company (The)(KO)

Advisors’ Opinion:

  • [By Shanthi Rexaline]

    Although estimates are not available, beverage giants such as PepsiCo, Inc. (NYSE: PEP), Dr Pepper Snapple Group Inc. (NYSE: DPS) and The Coca-Cola Co (NYSE: KO) also benefit from SNAP. When there was a move in 2011 to bring about restrictions on SNAP purchases, Pepsi reportedly spent $750,000 in the third quarter of 2011 on lobbying alone.

  • [By Jon C. Ogg]

    Coca-Cola Co.(NYSE: KO) was the exact same stake of 400 million shares. This has been a position thatalso has remained static, and Buffett has defended his stake here for years.

  • [By Ben Levisohn]

    Yes, Coca-Cola (KO) announced a CEO swap last week, but that has nothing to do with Morgan Stanley’s decision to cut Coca-Cola to Equal Weight from Overweight. Morgan Stanley analyst Dara Mohsenian and team explain what did:

    Getty Images

    We view Coke valuation as fair here, given topline challenges, with results limited by secular health/wellness challenges in developed markets and by weak macros in emerging markets. We also are even more cautious on large cap multinationals in general, given direct and indirect impacts from a Trump administration: 1) less favorable relative tax benefits from policy changes than domestic centric manufacturers, 2) the indirect impact of a strengthening US dollar, and 3) lower leverage to a potential US macro recovery from greater fiscal spending (which will have less impact on defensive large cap staples). Our downgrade is not related to the recent CEO change. We view James Quincey favorably, and we expect (and encourage) him to push harder on the favorable strategic changes Coke announced in October 2014.

    No matter. Shares of Coca-Cola have advanced 0.2% to $41.62 at 12:36 p.m. today.

stock market indicators: General Growth Properties, Inc.(GGP)

Advisors’ Opinion:

  • [By Paul Ausick]

    GGP Inc. (NYSE: GGP) posted a new 52-week low of $22.12 on Wednesday, down about 2.2% compared with Tuesday’s closing price of $22.61. The stock’s 52-week high is $32.10. Volume of around 4 million shares was about 20% below the daily average of around 5 million shares. The retail REIT had no specific news.

  • [By Chris Lange]

    The stock posting the largest daily percentage gain in the S&P 500 ahead of the close Tuesday was GGP Inc. (NYSE: GGP) which rose about 17% to $22.21. The stocks 52-week range is $18.83 to $27.10. Volume was about51 million compared to its average volume of 5.7 million.

  • [By Paul Ausick]

    GGP Inc. (NYSE: GGP) posted a new 52-week low of $21.05 on Wednesday, down about 8.6% from Tuesday’s closing price of $23.04. The stock’s 52-week high is $31.35. Volume totaled around 17 million shares, well over double the daily average of around 6.5 million. The REIT missed revenue estimates this morning.

stock market indicators: MGIC Investment Corporation(MTG)

Advisors’ Opinion:

  • [By Brian Feroldi, Chuck Saletta, Tyler Crowe, Jason Hall, and Jordan Wathen]

    With that in mind, we asked a team of Fools each to highlight a stock that a billionaire investor has been selling recently. Read on to see why they chose Cheniere Energy (NYSEMKT:LNG), Activision Blizzard (NASDAQ:ATVI), Suncor Energy (NYSE:SU), MGIC Investment Corporation (NYSE:MTG), and Extended Stay America (NYSE:STAY).

stock market indicators: NQ Mobile Inc.(NQ)

Advisors’ Opinion:

  • [By Lisa Levin]

    On Thursday, telecommunications services shares gained by 0.42 percent. Meanwhile, top gainers in the sector included 8×8, Inc. (NASDAQ: EGHT), up 4 percent, and NQ Mobile Inc (ADR) (NYSE: NQ), up 2 percent.

  • [By Lisa Levin]

    NQ Mobile Inc (ADR) (NYSE: NQ) shares dropped 16 percent to $3.88 after the company issued an update on the FL Mobile divestment. NQ Mobile is expected to report Q4 financial results on March 21, 2016.

  • [By Belinda Cao]

    Oberweis China Opportunities Fund (OBCHX), the best-performing U.S.-based fund investing in Chinese stocks, said Internet companies from NQ Mobile Inc. (NQ) to Qihoo 360 Technology Co. (QIHU) will extend a rally after jumping more than three-fold this year.

Hot Heal Care Stocks To Buy For 2018

Related AEE Benzinga's Top Downgrades Benzinga's Top Upgrades
Related WR Mid-Morning Market Update: Markets Open Lower; Lennar Beats Q1 Expectations Benzinga's Top Initiations

According to a report by Bloomberg, Westar Energy Inc (NYSE: WR) is a potential takeover target from rival Ameren Corp (NYSE: AEE) and a consortium of investors, including Toronto-based Borealis Infrastructure Management and the Canada Pension Plan Investment Board.

Westar oversees more than 30,000 miles of electrical transmissions and 700,000 customers.

Bloomberg, citing “people familiar with the matter,” noted that Westar is working with bankers to field interest in a sale and would begin evaluating bids next week. The publication added that Westar entertaining a sale for itself is consistent with recent heavy M&A activity within the utilities market.

Related Link: JPMorgan On Gas Utilities: Atmos Remains Undervalued, Nisource Downgraded

Hot Heal Care Stocks To Buy For 2018: Trevena, Inc.(TRVN)

Advisors’ Opinion:

  • [By Chris Lange]

    Trevena Inc. (NASDAQ: TRVN) reported positive results from two late-stage clinical trials that work to treat post-surgical pain. The company intends to submit these results to the FDA for a marketing approval agreement in the fourth quarter. Previously, oliceridine was approved for a breakthrough designation by the agency.

  • [By Paul Ausick]

    Trevena Inc. (NASDAQ: TRVN) dropped about 6.3% Thursday, to post a new 52-week low of $3.70 after closing at $3.95 on Wednesday. The stock’s 52-week high is $9.73. Volume was nearly 5 times the daily average of around 700,000 shares. The company’s pain-killing drug got mixed results in a trial result reported Tuesday.

  • [By Lisa Levin]

    Trevena Inc (NASDAQ: TRVN) shares dropped 36 percent to $4.55 despite a positive development in Phase 3 trials. Trevena announced positive top-line results from ongoing Phase 3 trials called "APOLLO-1" and "APOLLO-2." The studies evaluated the safety of Trevena's oliceridine therapy in patients for 48 hours following bunionectomy and 24 hours following abdominoplasty.

  • [By Maxx Chatsko]

    Shares of clinical-stage biopharma Trevena (NASDAQ:TRVN) fell nearly 12% today after it reported full-year 2016 earnings. The pre-revenue company didn’t announce any surprises one way or the other. However, investors appear to be considering the near-term consequences of swelling expenses that won’t be offset by product sales anytime soon.

  • [By Lisa Levin] Gainers
    Trevena Inc (NASDAQ: TRVN) rose 10.8 percent to $3.60 in pre-market trading after dropping 4.97 percent on Wednesday.
    Yum China Holdings Inc (NYSE: YUMC) rose 10.2 percent to $31.05 in pre-market trading after the company reported upbeat earnings for its first quarter.
    Seres Therapeutics Inc (NASDAQ: MCRB) rose 9.1 percent to $11.39 in pre-market trading after dropping 5.26 percent on Wednesday.
    Plug Power Inc (NASDAQ: PLUG) rose 8.9 percent to $2.45 in pre-market trading after surging 73.08 percent on Wednesday.
    Coach Inc (NYSE: COH) rose 6.7 percent to $41.98 in pre-market trading. Coach named Ian Bickley as President, Global Business Development and Strategic Alliances.
    Sapiens International Corporation N.V. (NASDAQ: SPNS) shares rose 6.1 percent to $13.91 in pre-market trading after gaining 0.54 percent on Wednesday.
    Jazz Pharmaceuticals plc (NASDAQ: JAZZ) rose 6.1 percent to $149.15 in pre-market trading. Jazz Pharma reached a settlement with Hikma Pharma related to Xyrem patent case. Mizuho downgraded Jazz from Buy to Neutral.
    Interactive Brokers Group, Inc. (NASDAQ: IBKR) shares rose 6 percent to $36.72 in pre-market trading after declining 0.03 percent on Wednesday.
    Rewalk Robotics Ltd (NASDAQ: RWLK) rose 5.3 percent to $2.00 in pre-market trading after the company disclosed that the U.S. Department of Veterans Affairs purchased 28 added Exoskeleton Systems.
    Merrimack Pharmaceuticals Inc (NASDAQ: MACK) rose 5.1 percent to $3.29 in pre-market trading. Merrimack declared a $1.06 special dividend.
    BioTime, Inc. (NYSE: BTX) shares rose 4.8 percent to $3.50 in pre-market trading. BioTime, reported the formation of new subsidiary AgeX Therapeutics, Inc.
    Akari Therapeutics PLC (ADR) (NASDAQ: AKTX) shares rose 4.8 percent to $12.26 in pre-market trading after gaining 0.69 percent on Wednesday.
    Bed Bath & Beyond Inc. (NASDAQ: BBBY) rose 3.6 percent to $39.15 in pre-market trading after the company posted better-than

Hot Heal Care Stocks To Buy For 2018: Century Aluminum Company(CENX)

Advisors’ Opinion:

  • [By Craig Jones]

    JPMorgan’s analyst Michael Gambardella downgraded Century Aluminum Co (NASDAQ: CENX) from Overweight to Neutral and reduced its price target from $22 to $14.50, citing alumina cost headwinds as the main reason for the downgrade.

Hot Heal Care Stocks To Buy For 2018: Monotype Imaging Holdings Inc.(TYPE)

Advisors’ Opinion:

  • [By Lisa Levin]

    Shares of Monotype Imaging Holdings Inc. (NASDAQ: TYPE) were down around 12 percent to $20.90 after the company posted downbeat quarterly earnings.

  • [By Lisa Levin]

    Wednesday afternoon, the non-cyclical consumer goods & services shares surged 0.61 percent. Meanwhile, top gainers in the sector included Monotype Imaging Holdings Inc. (NASDAQ: TYPE), up 9 percent, and Semiconductor Manufacturing Int'l (ADR) (NYSE: SMI), up 6 percent.

Best Blue Chip Stocks To Own Right Now

The stock market gave up ground on Tuesday, but investors saw major benchmarks recover from their worst levels of the day to finish down less than half a percent. Early in the day, poor earnings results from blue chip components of the Dow Jones Industrials weighed on market sentiment, and ongoing uncertainty about whether the Trump administration will be able to deliver on promised government reforms made some investors feel less confident about the future. However, several companies reported good news despite the dour mood on Wall Street, and GNC Holdings (NYSE:GNC), Stratasys (NASDAQ:SSYS), and Cabela’s (NYSE:CAB) were among the best performers on the day. Below, we’ll look more closely at these stocks to tell you why they did so well.

GNC eases shareholders’ concerns

Shares of GNC Holdings jumped 24% after the company posted first-quarter results that, while not perfect, were still not as bad as some investors had feared. Revenue fell 4% from year-ago levels, and same-store sales dropped 3.9% in company-owned locations and 4.6% in domestic franchise stores. Moreover, net income dropped by more than half, leaving the company with just $0.37 per share in adjusted earnings. Yet those numbers encouraged those who are patient enough to give GNC time to remake itself, and CEO Bob Moran pointed to the company’s One New GNC transformation strategy as having shown signs of early success. With new loyalty programs producing some positive effects on transaction counts and volume, GNC hopes that business metrics will hit bottom and start to grow again in the near future.

Best Blue Chip Stocks To Own Right Now: Gentex Corporation(GNTX)

Advisors’ Opinion:

  • [By Lisa Levin] Related TRST Earnings Scheduled For October 21, 2016 Major Accounting Changes Are Coming To The Financial Industry
    Related MORN One Of The World's Most Powerful Women, Fidelity Personal Investing President Kathleen Murphy, To Tell Her Story At The Benzinga Global Fintech Awards The 2017 Benzinga Global Fintech Awards Will Include An 'Unprecedented Group' Of Judges Morningstar Packs Conference Lineup For Financial Advisors (Investor’s Business Daily) Companies Reporting Before The Bell
    Rockwell Collins, Inc. (NYSE: COL) is estimated to report quarterly earnings at $1.31 per share on revenue of $1.33 billion.
    General Electric Company (NYSE: GE) is expected to report quarterly earnings at $0.17 per share on revenue of $26.46 billion.
    Honeywell International Inc. (NYSE: HON) is estimated to report quarterly earnings at $1.60 per share on revenue of $9.32 billion.
    Interpublic Group of Companies Inc (NYSE: IPG) is expected to report quarterly earnings at $0.03 per share on revenue of $1.76 billion.
    Schlumberger Limited. (NYSE: SLB) is estimated to report quarterly earnings at $0.26 per share on revenue of $7.02 billion.
    SunTrust Banks, Inc. (NYSE: STI) is expected to report quarterly earnings at $0.83 per share on revenue of $2.21 billion.
    ManpowerGroup Inc. (NYSE: MAN) is projected to report quarterly earnings at $1.11 per share on revenue of $4.68 billion.
    Kansas City Southern (NYSE: KSU) is estimated to report quarterly earnings at $1.15 per share on revenue of $593.82 million.
    Stanley Black & Decker, Inc. (NYSE: SWK) is projected to report quarterly earnings at $1.19 per share on revenue of $2.74 billion.
    WABCO Holdings Inc. (NYSE: WBC) is estimated to report quarterly earnings at $1.44 per share on revenue of $721.89 million.

Best Blue Chip Stocks To Own Right Now: Great Basin Scientific, Inc.(GBSN)

Advisors’ Opinion:

  • [By Paul Ausick]

    Great Basin Scientific Inc. (NASDAQ: GBSN) dropped about 15% on Thursday to post a new 52-week low of $2.90 after closing at $3.42 on Wednesday. The stock’s 52-week high is $45,024.00. Volume was more than 3 times the daily average of around 150,000 shares. The medical diagnostics company had no specific news Thursday. Since mid-March the company has split the stock twice: the first was a 1-for-35 split and the second a 1-for-80 split.

  • [By Lisa Levin]

    Great Basin Scientific Inc (NASDAQ: GBSN) shares dropped 18 percent to $0.92 on Q1 results. Great Basin Scientific posted Q1 net income of $21,503,600, versus a year-ago net loss of $33,652,500.

Best Blue Chip Stocks To Own Right Now: Trevena, Inc.(TRVN)

Advisors’ Opinion:

  • [By Lisa Levin] Gainers
    Trevena Inc (NASDAQ: TRVN) rose 10.8 percent to $3.60 in pre-market trading after dropping 4.97 percent on Wednesday.
    Yum China Holdings Inc (NYSE: YUMC) rose 10.2 percent to $31.05 in pre-market trading after the company reported upbeat earnings for its first quarter.
    Seres Therapeutics Inc (NASDAQ: MCRB) rose 9.1 percent to $11.39 in pre-market trading after dropping 5.26 percent on Wednesday.
    Plug Power Inc (NASDAQ: PLUG) rose 8.9 percent to $2.45 in pre-market trading after surging 73.08 percent on Wednesday.
    Coach Inc (NYSE: COH) rose 6.7 percent to $41.98 in pre-market trading. Coach named Ian Bickley as President, Global Business Development and Strategic Alliances.
    Sapiens International Corporation N.V. (NASDAQ: SPNS) shares rose 6.1 percent to $13.91 in pre-market trading after gaining 0.54 percent on Wednesday.
    Jazz Pharmaceuticals plc (NASDAQ: JAZZ) rose 6.1 percent to $149.15 in pre-market trading. Jazz Pharma reached a settlement with Hikma Pharma related to Xyrem patent case. Mizuho downgraded Jazz from Buy to Neutral.
    Interactive Brokers Group, Inc. (NASDAQ: IBKR) shares rose 6 percent to $36.72 in pre-market trading after declining 0.03 percent on Wednesday.
    Rewalk Robotics Ltd (NASDAQ: RWLK) rose 5.3 percent to $2.00 in pre-market trading after the company disclosed that the U.S. Department of Veterans Affairs purchased 28 added Exoskeleton Systems.
    Merrimack Pharmaceuticals Inc (NASDAQ: MACK) rose 5.1 percent to $3.29 in pre-market trading. Merrimack declared a $1.06 special dividend.
    BioTime, Inc. (NYSE: BTX) shares rose 4.8 percent to $3.50 in pre-market trading. BioTime, reported the formation of new subsidiary AgeX Therapeutics, Inc.
    Akari Therapeutics PLC (ADR) (NASDAQ: AKTX) shares rose 4.8 percent to $12.26 in pre-market trading after gaining 0.69 percent on Wednesday.
    Bed Bath & Beyond Inc. (NASDAQ: BBBY) rose 3.6 percent to $39.15 in pre-market trading after the company posted better-than
  • [By Paul Ausick]

    Trevena Inc. (NASDAQ: TRVN) dropped about 6.3% Thursday, to post a new 52-week low of $3.70 after closing at $3.95 on Wednesday. The stock’s 52-week high is $9.73. Volume was nearly 5 times the daily average of around 700,000 shares. The company’s pain-killing drug got mixed results in a trial result reported Tuesday.

  • [By Lisa Levin]

    Trevena Inc (NASDAQ: TRVN) shares dropped 36 percent to $4.55 despite a positive development in Phase 3 trials. Trevena announced positive top-line results from ongoing Phase 3 trials called "APOLLO-1" and "APOLLO-2." The studies evaluated the safety of Trevena's oliceridine therapy in patients for 48 hours following bunionectomy and 24 hours following abdominoplasty.

  • [By Maxx Chatsko]

    Shares of clinical-stage biopharma Trevena (NASDAQ:TRVN) fell nearly 12% today after it reported full-year 2016 earnings. The pre-revenue company didn’t announce any surprises one way or the other. However, investors appear to be considering the near-term consequences of swelling expenses that won’t be offset by product sales anytime soon.

  • [By Chris Lange]

    Trevena Inc. (NASDAQ: TRVN) reported positive results from two late-stage clinical trials that work to treat post-surgical pain. The company intends to submit these results to the FDA for a marketing approval agreement in the fourth quarter. Previously, oliceridine was approved for a breakthrough designation by the agency.